Bristol-Myers Squibb PE Ratio 2006-2018 | BMY

Current and historical p/e ratio for Bristol-Myers Squibb (BMY) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bristol-Myers Squibb PE ratio as of October 22, 2018 is 15.05.
Bristol-Myers Squibb PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-10-22 50.88 221.22
2018-06-30 54.95 $0.23 238.90
2018-03-31 62.40 $0.56 111.43
2017-12-31 60.07 $0.59 101.81
2017-09-30 62.10 $2.54 24.45
2017-06-30 53.91 $2.75 19.60
2017-03-31 52.23 $2.88 18.14
2016-12-31 55.76 $2.65 21.04
2016-09-30 51.10 $2.04 25.05
2016-06-30 69.70 $1.74 40.06
2016-03-31 60.22 $0.97 62.08
2015-12-31 64.46 $0.97 66.46
2015-09-30 55.18 $1.06 52.05
2015-06-30 61.30 $1.07 57.29
2015-03-31 59.07 $1.35 43.76
2014-12-31 54.06 $1.20 45.05
2014-09-30 46.25 $1.63 28.38
2014-06-30 43.52 $1.62 26.86
2014-03-31 46.28 $1.74 26.60
2013-12-31 47.35 $1.55 30.55
2013-09-30 40.65 $1.67 24.34
2013-06-30 38.94 $0.82 47.49
2013-03-31 35.59 $0.88 40.44
2012-12-31 27.86 $1.15 24.23
2012-09-30 28.56 $1.09 26.20
2012-06-30 30.13 $2.08 14.49
2012-03-31 28.01 $2.22 12.61
2011-12-31 28.95 $2.15 13.47
2011-09-30 25.52 $1.93 13.22
2011-06-30 23.56 $1.92 12.27
2011-03-31 21.25 $1.93 11.01
2010-12-31 20.77 $1.79 11.60
2010-09-30 21.26 $5.57 3.82
2010-06-30 19.33 $5.50 3.52
2010-03-31 20.44 $5.46 3.74
2009-12-31 19.10 $5.35 3.57
2009-09-30 16.82 $1.92 8.76
2009-06-30 14.74 $2.73 5.40
2009-03-31 15.69 $2.62 5.99
2008-12-31 16.64 $2.63 6.33
2008-09-30 14.51 $1.95 7.44
2008-06-30 14.07 $1.09 12.91
2008-03-31 14.39 $1.07 13.45
2007-12-31 17.71 $1.09 16.25
2007-09-30 19.07 $1.07 17.82
2007-06-30 20.70 $0.81 25.55
2007-03-31 18.02 $0.79 22.81
2006-12-31 16.91 $0.80 21.13
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $83.165B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $372.065B 17.44
Pfizer (PFE) United States $264.129B 15.46
Novartis AG (NVS) Switzerland $201.850B 17.25
Merck (MRK) United States $195.663B 17.28
AbbVie (ABBV) United States $127.608B 12.47
Eli Lilly (LLY) United States $120.319B 22.27
Sanofi (SNY) France $111.710B 14.14
Novo Nordisk (NVO) Denmark $105.365B 16.84
GlaxoSmithKline (GSK) United Kingdom $100.437B 13.41
AstraZeneca (AZN) United Kingdom $100.024B 11.00